References
- FROSTL W: First joint French-Swiss meeting on medici-nal chemistry (Dijon, France). Curr. (in. Invest. Drugs (1993) 2:1233–1236.
- KOHL NE, MOSSER SD, JANE DE SOLMS 5, GIULIANI EA,POMPLIANO DL, GRAHAM SL, SMITH RL, SCOLNICK EM, 01.1:FF A, GIBBS JB: Selective inhibition of ras dependent transformations by a farnesyltransferase inhibitor. Sci-ence (1993) 260:19341 937.
- JAMES GL, GOLDSTEIN JL, BROWN MS, RAWSON TE,SOMERS TC, MCDOWELL RS, CROWLEY CW, LUCAS BK, LEVINSON AD, MARSTERS JC: Benzodiazepine pepti-domirnetics: potent inhibitors of ras farnesylation In animal cells. Science (1993) 260:1937–1942.
- GARCIA AM, ROWELL C, ACKERMANN K, KOWALCZYK JJ,LEWIS MD: Peptidomirnetic inhibitors of ras farnesyla-tion and function in whole cells. J. Biol. Chem. (1993) 268:18415–18418.
- NIGAM M, SEONG CM, QIAN Y, HAMILTON AD, SEBTI SM:Potent inhibition of human tumor p2lras farnesyltrans-ferase by AiA2-lacking p21 CAIA2X peptidomimetics. J. Biol. Chem. (1993) 268:20695–20698.
- SCHUCFITER LM, ESA AH, STRATFORD MAY W, LAULIS MK,PETTIT GR, HESS AD: Successful treatment of murine melanoma with bryostatin L Cancer Res. (1991) 51:682–687.
- CHO-CHUNG YS: Site-selective 8-chloro-cyclic adeno-sine 3',5'-monophosphate as a biologic modulator of cancer: restoration of normal control mechanisms. J. Natl. Cancer Inst. (1989) 81:982–987.
- KOHN EC, LIOTTA LA: L651582: A novel antiproliferativeand antimetastasis agent. J. Natl. Cancer Inst. (1990) 82:54–60.
- CROWELL PL, CHANG RR, REN Z, ELSON CE, GOULD MN:Selective inhibition of isoprenylation of 21-26 Ic.Da proteins by the anticarcinogen d-limonene and its metabolites. J. Biol. Chem. (1991) 266:17679–17685.